GRF Stock Analysis: Grifols S.A. | MC
Drug Manufacturers - General | MC, Spain | Market Cap: 6.137m EUR | 12M Return: -19.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.1M
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Grifols, S.A. is a Spanish healthcare company headquartered in Barcelona that researches, develops, produces, and markets plasma-derived medicines and related diagnostic and hospital products, operating through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. Its Biopharma business focuses on hemoderivatives from human plasma for therapeutic areas including immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology, as well as albumin, immunoglobulins, thrombin, and intermediate plasma products supplied to other pharma and biotech firms. The Diagnostic and Bio Supplies segments cover transfusion medicine, clinical diagnostics equipment and reagents, and processed plasma and clinical samples for life-science research, while the Others segment delivers hospital solutions such as intravenous fluids, clinical nutrition, and medical devices used in interventional neuroradiology, hemodynamics, urology, anesthesiology, and cardiovascular surgery.
The company sells its products in the United States, Canada, Spain, Europe, and other international markets, and also conducts ancillary activities such as engineering, packaging and contract manufacturing, import/export commercialization, reinsurance, and consulting services. Grifols was founded in 1909 and is listed on the Madrid stock exchange.
The plasma-derived medicines sector relies on a vertically integrated, plasma-collection-dependent supply chain, where access to and fractionation capacity of human plasma are key competitive drivers for industry participants.
- Immunoglobulin volume growth in Biopharma segment lifts revenue
- Elevated debt levels and refinancing costs squeeze profit margins
- Plasma collection supply recovery supports Biopharma gross margin expansion
| Net Income: 415.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.72 > 1.0 |
| NWC/Revenue: 42.08% < 20% (prev 47.06%; Δ -4.99% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.02b > Net Income 415.2m |
| Net Debt (9.99b) to EBITDA (1.43b): 6.98 < 3 |
| Current Ratio: 2.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.6m) vs 12m ago 0.02% < -2% |
| Gross Margin: 37.68% > 18% (prev 39.39%; Δ -1.71% > 0.5%) |
| Asset Turnover: 36.23% > 50% (prev 35.14%; Δ 1.09% > 0%) |
| Interest Coverage Ratio: 1.76 > 6 (EBIT TTM 1.08b / Interest Expense TTM 614.6m) |
| A: 0.16 (Total Current Assets 5.25b - Total Current Liabilities 2.12b) / Total Assets 20.1b |
| B: 0.00 (Retained Earnings 73.0m / Total Assets 20.1b) |
| C: 0.05 (EBIT TTM 1.08b / Avg Total Assets 20.5b) |
| D: 0.45 (Book Value of Equity 5.46b / Total Liabilities 12.2b) |
| Altman-Z'' = 1.86 = BBB |
| DSRI: 0.91 (Receivables 958.0m/1.04b, Revenue 7.44b/7.37b) |
| GMI: 1.05 (GM 39.39% / 37.68%) |
| AQI: 1.01 (AQ_t 0.58 / AQ_t-1 0.58) |
| SGI: 1.01 (Revenue 7.44b / 7.37b) |
| TATA: -0.03 (NI 415.2m - CFO 1.02b) / TA 20.1b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at EUR 8.99 with a total of 1,257,817 shares traded. Over the past week, the price has changed by -1.30%, over one month by +1.45%, over three months by +2.02% and over the past year by -19.50%.
Current recommended Stop Loss: 8.70 (which is 3.2% or 1.5 ATR below the current price).
Grifols S.A. has no consensus analysts rating.
P/E Trailing = 14.7836
P/E Forward = 11.7371
P/S = 0.8251
P/B = 1.112
P/EG = 0.283
Revenue TTM = 7.44b EUR
EBIT TTM = 1.08b EUR
EBITDA TTM = 1.43b EUR
Long Term Debt = 8.07b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 589.0m EUR (from shortTermDebt, last quarter)
Debt = 10.8b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.08b
Net Debt = 9.99b EUR (calculated: Debt 10.8b - CCE 758.0m)
Enterprise Value = 16.1b EUR (6.14b + Debt 10.8b - CCE 758.0m)
Interest Coverage Ratio = 1.76 (Ebit TTM 1.08b / Interest Expense TTM 614.6m)
EV/FCF = 21.40x (Enterprise Value 16.1b / FCF TTM 753.7m)
FCF Yield = 4.67% (FCF TTM 753.7m / Enterprise Value 16.1b)
FCF Margin = 10.13% (FCF TTM 753.7m / Revenue TTM 7.44b)
Net Margin = 5.58% (Net Income TTM 415.2m / Revenue TTM 7.44b)
Gross Margin = 37.68% ((Revenue TTM 7.44b - Cost of Revenue TTM 4.64b) / Revenue TTM)
Gross Margin QoQ = 36.47% (prev 34.68%)
Tobins Q-Ratio = 0.80 (Enterprise Value 16.1b / Total Assets 20.1b)
Interest Expense / Debt = 5.72% (Interest Expense 614.6m / Debt 10.8b)
Taxrate = 18.92% (115.8m / 611.8m)
NOPAT = 877.3m (EBIT 1.08b * (1 - 18.92%))
Current Ratio = 2.47 (Total Current Assets 5.25b / Total Current Liabilities 2.12b)
Debt / Equity = 1.97 (Debt 10.8b / totalStockholderEquity, last quarter 5.46b)
Debt / EBITDA = 6.98 (Net Debt 9.99b / EBITDA 1.43b)
Debt / FCF = 13.26 (Net Debt 9.99b / FCF TTM 753.7m)
Total Stockholder Equity = 5.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.02% (Net Income 415.2m / Total Assets 20.1b)
RoE = 7.88% (Net Income TTM 415.2m / Total Stockholder Equity 5.27b)
RoCE = 8.11% (EBIT 1.08b / Capital Employed (Equity 5.27b + L.T.Debt 8.07b))
RoIC = 4.83% (NOPAT 877.3m / Invested Capital 18.2b)
WACC = 5.51% (E(6.14b)/V(16.9b) * Re(7.04%) + D(10.8b)/V(16.9b) * Rd(5.72%) * (1-Tc(0.19)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.98 | Cagr: 0.10%
[DCF] Terminal Value 73.10% ; FCFF base≈827.6m ; Y1≈725.8m ; Y5≈586.4m
[DCF] Fair Price = N/A (negative equity: EV 9.41b - Net Debt 9.99b = -580.6m; debt exceeds intrinsic value)
EPS Correlation: 94.40 | EPS CAGR: 54.55% | SUE: -0.48 | # QB: 0
Revenue Correlation: 96.50 | Revenue CAGR: 6.66% | SUE: -0.73 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.24 | Chg30d=N/A | Revisions=+25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.25 | Chg30d=N/A | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.85 | Chg30d=+0.00% | Revisions=-22% | GrowthEPS=+16.1% | GrowthRev=+2.0%
EPS next Year (2027-12-31): EPS=1.11 | Chg30d=+0.00% | Revisions=-70% | GrowthEPS=+31.0% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: -50% (up=3, down=12)